Haas Naomi B, Uzzo Robert G
Department of Medical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA 19111, USA.
Urol Oncol. 2007 Sep-Oct;25(5):420-32. doi: 10.1016/j.urolonc.2007.05.009.
Renal cell carcinoma (RCC) is the most lethal of all genitourinary malignancies with nearly half of all patients presenting with locally advanced or metastatic disease. Systemic treatments such as chemo- or immunotherapy have historically been associated with overall response rates of 5-15% with very few durable responses. The basis of newly approved, more effective targeted therapies for metastatic RCC are based on a fundamental knowledge of the molecular mechanisms that give rise to RCC. We review the clinical data for targeted therapies in RCC and discuss the pertinent biology, side effects, and targets important to the practicing clinician.
肾细胞癌（RCC）是所有泌尿生殖系统恶性肿瘤中致死率最高的，近一半患者初诊时即表现为局部晚期或转移性疾病。传统上，化疗或免疫疗法等全身治疗的总体缓解率为5%-15%，持久缓解的情况非常罕见。新批准的、更有效的转移性RCC靶向治疗的基础是对导致RCC的分子机制的基本认识。我们回顾了RCC靶向治疗的临床数据，并讨论了相关生物学、副作用以及对临床医生重要的靶点。
